Current Diabetes Reports

, Volume 10, Issue 2, pp 116-123

First online:

Update on the Safety of Thiazolidinediones

  • David C. LiebAffiliated withDepartment of Medicine, Strelitz Diabetes Center for Endocrine and Metabolic Disorders Email author 
  • , Anthony L. McCallAffiliated withDepartment of Medicine, University of Virginia Health System

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Diabetic patients are at increased risk for developing cardiovascular disease, and they constitute a large proportion of the global cardiovascular disease burden. Although multiple drugs exist for treating the hyperglycemia associated with diabetes, few have been shown to reduce cardiovascular risk. Great hope surrounded the arrival of the thiazolidinediones—drugs that favorably affect insulin sensitivity, inflammation, and some aspects of lipid profiles in diabetic patients. However, the cardiovascular effects of these agents are varied, and studies have suggested that they may be associated with increases in ischemic heart disease and heart failure, as well as with an increased risk for bone fracture. The following article provides a summary of important studies that have been published regarding the safety profiles of these agents. Findings from two recently published trials, RECORD and BARI 2D, are emphasized in this paper.


Thiazolidinediones Cardiovascular disease Rosiglitazone Pioglitazone